Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rotavirus vaccine, live attenuated, bovine-human reassortant, pentavalent + diphtheria-tetanus-pertussis (whole cell)-hepatitis B-haemophilus influenzae type b vaccine + oral polio vaccine
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral, Intramuscular
01
Overview
A combination immunization regimen consisting of Rotasiil (BRV-PV), a live attenuated bovine-human reassortant pentavalent rotavirus vaccine, co-administered with a pentavalent DTwP-HepB-Hib vaccine and oral polio vaccine (OPV). Developed by the Serum Institute of India, Rotasiil is the world's first thermostable rotavirus vaccine, targeting serotypes G1, G2, G3, G4, and G9. This specific regimen was evaluated in Phase 3 clinical trials in India to assess lot-to-lot consistency and ensure that co-administration does not interfere with the immunogenicity of routine Universal Immunisation Programme (UIP) vaccines in infants.
- Brand names
- ROTASIIL
- Other names
- Bovine Rotavirus Pentavalent Vaccine + DTwP-HepB-Hib + OPV
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on rotavirus vaccine, live attenuated, bovine-human reassortant, pentavalent + diphtheria-tetanus-pertussis (whole cell)-hepatitis B-haemophilus influenzae type b vaccine + oral polio vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rotavirus vaccine, live attenuated, bovine-human reassortant, pentavalent + diphtheria-tetanus-pertussis (whole cell)-hepatitis B-haemophilus influenzae type b vaccine + oral polio vaccine.